Kenn Holmbeck

Kenn Holmbeck is an Associate Professor in the Department of Immunology and Microbiology at the University of Copenhagen's Faculty of Health and Medical Sciences. His research focuses on virology, particularly hepatitis C virus (HCV) and SARS-CoV-2, with expertise in viral evolution, immune responses, and vaccine development. He employs both in vitro systems and animal models to investigate viral pathogenesis and develop novel therapeutic approaches.

Dr. Holmbeck's research encompasses viral evolution dynamics, immune evasion mechanisms, and vaccine platform development. His work on HCV includes studying intra-host viral evolution, antibody escape mechanisms, and developing the Norway rat hepacivirus as a model system. For SARS-CoV-2, he investigates antiviral resistance pathways and develops innovative vaccine platforms including intranasal and inactivated vaccines that induce robust cross-protective immunity.

Analysis of Dr. Holmbeck's recent publications (2023-2025) reveals a cohesive research program focused on viral pathogenesis and translational vaccine development. His work demonstrates expertise across multiple viral systems with particular emphasis on understanding how viruses evolve under immune or drug pressure and leveraging this knowledge to develop effective countermeasures. Key themes include viral adaptation mechanisms, neutralizing antibody responses, and the development of vaccine platforms that induce durable and cross-reactive immune protection.

Dr. Holmbeck maintains extensive collaborative networks across virology research, as evidenced by his co-authorship on numerous high-impact publications in journals including PLOS Pathogens, Journal of Hepatology, Hepatology, and EBioMedicine. His research likely involves securing competitive grants to support laboratory work on viral pathogenesis and vaccine development, with publications indicating active involvement in both basic and translational research projects.

Based on publication patterns, Dr. Holmbeck leads or is a key member of a research team with capabilities spanning molecular virology, animal challenge studies, and vaccine evaluation. His laboratory likely includes facilities for viral culture, sequencing, neutralization assays, and small animal studies, supporting a comprehensive approach to understanding viral pathogenesis and developing effective interventions.